CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 10 enrolled
Drug / intervention
Eight Percent Topical Capsaicindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03899246
NCT03899246Phase 1Completed
CompareCT.gov

Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease

Children's Hospital of Michigan·interventional·Posted Apr 2, 2019·Updated Jul 29, 2020

In Brief

A Phase 1 clinical trial evaluating Eight Percent Topical Capsaicin for Neuropathic Pain and Sickle Cell Disease. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This study evaluates the safety and feasibility of using high dose topical capsaicin patches for the treatment of neuropathic pain in pediatric patients with sickle cell disease, as well as the feasibility of using a number of tests for the evaluation and monitoring of neuropathic pain. The hypothesis, based on evidence obtained from studies in adults with neuropathic pain related to other diseases as well as a single previously published study of capsaicin in pediatric patients, is that capsaicin will be well tolerated in this population. Additionally, it is hypothesized that it is feasible to monitor changes in neuropathic pain via the testing listed below.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain, Sickle Cell Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedApr 2, 2019
Enrollment StartJul 3, 2019
Primary CompletionMar 30, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.3 years ago

Interventions

Eight Percent Topical Capsaicindrug

See arm description